BamSEC and AlphaSense Join Forces
Learn More

Entrada Therapeutics Inc. – Material Contracts

NASDAQ: TRDA    
Share price (6/11/26): $6.31    
Market cap (6/11/26): $245 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 1 page Amendment No. 1 to the 2021 Employee Stock Purchase Plan
12/34/56
EX-10.1
from 8-K 1 page Amendment No. 1 to the 2021 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 10-Q 3 pages Entrada Therapeutics, Inc. Third Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.2
from 10-K 51 pages Material contract
12/34/56
EX-10.3
from 10-Q 3 pages Entrada Therapeutics, Inc. Second Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.2
from 8-K 17 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 22 pages Securities Purchase Agreement
12/34/56
EX-10.17
from 10-K 52 pages Sublicense Agreement Between Vertex Pharmaceuticals Incorporated and Entrada Therapeutics, Inc. December 7, 2022 Sublicense Agreement
12/34/56
EX-10.16
from 10-K 78 pages Strategic Collaboration and License Agreement Between Vertex Pharmaceuticals Incorporated and Entrada Therapeutics, Inc. December 7, 2022 Strategic Collaboration and License Agreement
12/34/56
EX-10.14
from 10-K 44 pages Lease Idb 17-19 Drydock Limited Partnership, a Delaware Limited Partnership Landlord and Entrada Therapeutics, Inc., a Delaware Corporation Tenant for the Innovation and Design Building Premises Located on the Fifth (5th) and Sixth (6th) Floors of One Design Center Place Boston, Massachusetts March 16, 2022
12/34/56
EX-10.13
from 10-K 41 pages Exclusive License Agreement Agt. No
12/34/56
EX-10.2
from 8-K 3 pages Amendment No. 1 to the Sublicense Agreement
12/34/56
EX-10.1
from 8-K 3 pages Amendment No. 1 to the Strategic Collaboration and License Agreement
12/34/56
EX-10.18
from 10-Q 2 pages Entrada Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.17
from 10-Q 49 pages Sublicense Agreement Between Vertex Pharmaceuticals Incorporated and Entrada Therapeutics, Inc. December 7, 2022 Sublicense Agreement
12/34/56
EX-10.16
from 10-Q 75 pages Strategic Collaboration and License Agreement Between Vertex Pharmaceuticals Incorporated and Entrada Therapeutics, Inc. December 7, 2022 Strategic Collaboration and License Agreement
12/34/56
EX-10.17
from 10-K 49 pages Sublicense Agreement Between Vertex Pharmaceuticals Incorporated and Entrada Therapeutics, Inc. December 7, 2022 Sublicense Agreement
12/34/56
EX-10.16
from 10-K 75 pages Strategic Collaboration and License Agreement Between Vertex Pharmaceuticals Incorporated and Entrada Therapeutics, Inc. December 7, 2022 Strategic Collaboration and License Agreement
12/34/56
EX-10.1
from 8-K 29 pages Stock Purchase Agreement by and Between Entrada Therapeutics, Inc. and Vertex Pharmaceuticals Incorporated Dated as of December 7, 2022
12/34/56
EX-10.1
from 8-K 61 pages Lease Idb 17-19 Drydock Limited Partnership, a Delaware Limited Partnership Landlord and Entrada Therapeutics, Inc., a Delaware Corporation Tenant for the Innovation and Design Building Premises Located on the Fifth (5th) and Sixth (6th) Floors of One Design Center Place Boston, Massachusetts March 16, 2022
12/34/56